Sun Pharma settles Excelon case with Novartis

New Delhi, Dec 6 (UNI) Sun Pharmaceutical Industries Ltd today said it has executed a settlement agreement with Novartis stipulating a dismissal of the lawsuits filed in the US against the company regarding submission of an abbreviated new drug application (ANDA) for a generic version of Exelon, rivastigmine tartrate capsules.

Under the terms of the settlement agreement, Sun Pharma will not market generic Exelon in the US until sometime prior to the expiration of the patents covering Exelon. The specific date on which Sun may launch and the other terms of the agreement are confidential, a company statement said.

Earlier, USFDA had granted final approval for the company's ANDA to market its generic Exelon, the statement added.

UNI